Trial Profile
Study of a sitafloxacin - containing regimen for relapsed or refractory pulmonary mycobacterium avium complex disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2016
Price :
$35
*
At a glance
- Drugs Sitafloxacin (Primary)
- Indications Mycobacterium avium complex infections
- Focus Therapeutic Use
- 29 Jun 2016 New trial record
- 18 May 2016 Preliminary results presented at the 112th International Conference of the American Thoracic Society